Appili therapeutics joins dr. reddy's, global response aid, and fujifilm in advancing avigan® tablets for the potential treatment of covid-19

Halifax, nova scotia--(business wire)--appili therapeutics inc. (tsx: apli; otcqx: aplif) (the “company” or “appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has signed a collaboration, development and supply agreement with dr. reddy's laboratories ltd. (bse:500124, nse:drreddy, nyse:rdy, “dr. reddy's”) and global response aid (“gra”). this agreement follows on and is harmonized with the previously announced global licensing transaction (
RDY Ratings Summary
RDY Quant Ranking